Pharmaceutical Preparations
Standard Industrial Classification: SIC 2834
Industry Insider Sentiment Analysis
The Pharmaceutical Preparations sector (SIC 2834) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 21:10 | 2026-11-17 | LEGN | Legend Biotech Corp | Zhang Ingrid | Officer | BUY | $8.16 | 20,000 | $163,200 | 1,151,860 |
| 2026-11-21 01:59 | 2026-11-18 | BOLD | Boundless Bio, Inc. | TANG KEVIN | 10% owner | BUY | $2.36 | 103,612 | $244,234 | 3,152,991 |
| 2026-11-21 00:00 | 2026-11-18 | SLS | SELLAS Life Sciences Group, Inc. | Stergiou Angelos M. | Director, Officer | SELL | $19.18 | 26,606 | $510,250 | 1,734,896 |
| 2026-11-21 00:00 | 2026-11-18 | SLS | SELLAS Life Sciences Group, Inc. | CICIC DRAGAN | Officer | SELL | $19.18 | 6,933 | $132,961 | 557,361 |
| 2026-11-21 00:01 | 2026-11-18 | SLS | SELLAS Life Sciences Group, Inc. | Burns John Thomas | Officer | SELL | $19.18 | 3,831 | $73,471 | 558,893 |
| 2026-11-20 22:28 | 2026-11-19 | LPCN | Lipocine Inc. | Higuchi John W. | Director | BUY | $1.50 | 150,000 | $225,225 | 391,365 |
| 2026-11-20 22:10 | 2026-11-19 | AEON | AEON Biopharma, Inc. | Sy Jennifer | Officer | BUY | $0.13 | 153,846 | $19,985 | 1,655,022 |
| 2026-11-20 22:11 | 2026-11-20 | AEON | AEON Biopharma, Inc. | Wilson Alexander Blair | Officer | BUY | $0.13 | 135,706 | $17,479 | 2,318,711 |
| 2026-11-20 21:58 | 2026-11-18 | RCKT | ROCKET PHARMACEUTICALS, INC. | Shah Gaurav | Officer | SELL | $2.18 | 2,216 | $4,826 | 1,051,358 |
| 2026-11-20 22:00 | 2026-11-19 | CRMD | CorMedix Inc. | Blum Susan | Officer | BUY | $4.58 | 5,000 | $22,900 | 129,315 |
| 2026-11-20 22:08 | 2026-11-19 | AEON | AEON Biopharma, Inc. | Bancroft Robert E. | Director, Officer | BUY | $0.13 | 152,333 | $19,590 | 3,329,436 |
| 2026-11-20 21:50 | 2026-11-20 | ORKA | Oruka Therapeutics, Inc. | Quinlan Paul T | Officer | OPT+S | $94.89 | 9,000 | $853,986 | 29,995 |
| 2026-11-20 21:54 | 2026-11-18 | RCKT | ROCKET PHARMACEUTICALS, INC. | Wilson Martin | Officer | SELL | $2.18 | 677 | $1,475 | 540,336 |
| 2026-11-20 21:28 | 2026-11-18 | RYTM | RHYTHM PHARMACEUTICALS, INC. | Shulman Joseph | Officer | OPT+S | $119.90 | 45,921 | $5,506,153 | 10,461 |
| 2026-11-20 21:33 | 2026-11-19 | INSM | INSMED Inc | Schaeffer Orlov S Nicole | Officer | OPT+S | $145.26 | 101,100 | $14,685,604 | 41,895 |
| 2026-11-20 21:33 | 2026-11-18 | BBIO | BridgeBio Pharma, Inc. | Kumar Neil | Director, Officer | SELL | $77.86 | 54,980 | $4,280,759 | 475,686 |
| 2026-11-20 21:15 | 2026-11-18 | BBOT | BridgeBio Oncology Therapeutics, Inc. | Beltran Pedro | Director, Officer | SELL | $1.84 | 1,870 | $3,443 | 41,659 |
| 2026-11-20 21:05 | 2026-11-19 | ANNX | Annexon, Inc. | Carson William H. | Director | BUY | $3.58 | 34,000 | $121,720 | 112,405 |
| 2026-11-20 21:05 | 2026-11-19 | DARE | Dare Bioscience, Inc. | RASTETTER WILLIAM H | Director | SELL | $0.45 | 859 | $382 | 0 |
| 2026-11-20 18:34 | 2026-11-18 | CRMD | CorMedix Inc. | Lefkowitz Steven W | Director | BUY | $4.53 | 11,500 | $52,095 | 137,451 |
| 2026-11-20 13:41 | 2026-11-18 | NMAD | NOMAD POWER SOLUTIONS, INC. | Holloway Michael Andrew | Director | BUY | $2.82 | 15,000 | $42,300 | 55,000 |
| 2026-11-20 13:45 | 2026-11-18 | IMMX | Immix Biopharma, Inc. | Morris Gabriel S | Director, Officer | BUY | $7.06 | 1,418 | $10,011 | 292,847 |
| 2026-11-20 13:45 | 2026-11-18 | IMMX | Immix Biopharma, Inc. | Rachman Ilya M | Director, Officer | BUY | $7.10 | 1,408 | $10,000 | 1,143,091 |
| 2026-11-20 13:19 | 2026-11-18 | FLNA | FILANA THERAPEUTICS, INC. | Barry Richard | Director, Officer | BUY | $0.52 | 44,851 | $23,323 | 1,955,947 |
| 2026-11-20 13:22 | 2026-11-18 | FLNA | FILANA THERAPEUTICS, INC. | Anderson Robert Eugene Jr | Director | BUY | $0.52 | 19,000 | $9,880 | 27,600 |
| 2026-11-19 21:30 | 2026-11-17 | NBP | NovaBridge Biosciences | Hagler Mark Arnold | Officer | BUY | $0.37 | 230,000 | $85,882 | 460,000 |
| 2026-11-19 21:02 | 2026-11-17 | FLNA | FILANA THERAPEUTICS, INC. | Barry Richard | Director, Officer | BUY | $0.48 | 132,926 | $63,804 | 1,911,096 |
| 2026-11-20 02:51 | 2026-11-19 | AVIR | Atea Pharmaceuticals, Inc. | Polsky Bruce | Director | SELL | $4.03 | 8,750 | $35,298 | 149,830 |
| 2026-11-20 02:51 | 2026-11-17 | AVIR | Atea Pharmaceuticals, Inc. | Lucidi Bruno | Director | OPT+S | $3.96 | 29,360 | $116,409 | 187,990 |
| 2026-11-20 02:03 | 2026-11-18 | CRVO | CervoMed Inc. | ALAM JOHN J | Director, Officer, 10% owner | BUY | $1.53 | 100,000 | $152,620 | 1,584,078 |
| 2026-11-19 23:40 | 2026-11-19 | KURA | Kura Oncology, Inc. | Powl Brian T. | Officer | SELL | $7.27 | 448 | $3,257 | 112,817 |
| 2026-11-19 23:41 | 2026-11-19 | UTHR | UNITED THERAPEUTICS Corp | MAHON PAUL A | Officer | OPT+S | $565.09 | 8,300 | $4,690,229 | 45,172 |
| 2026-11-19 23:50 | 2026-11-17 | NKTR | NEKTAR THERAPEUTICS | Zalevsky Jonathan | Officer | SELL | $35.85 | 192 | $6,883 | 9,378 |
| 2026-11-19 23:50 | 2026-11-17 | NKTR | NEKTAR THERAPEUTICS | ROBIN HOWARD W | Director, Officer | SELL | $35.85 | 429 | $15,380 | 54,198 |
| 2026-11-19 23:28 | 2026-11-17 | TNGX | Tango Therapeutics, Inc. | Ketchum John B | Director | SELL | $24.08 | 3,333 | $80,259 | 21,604 |
| 2026-11-19 22:59 | 2026-11-17 | FBIO | Fortress Biotech, Inc. | ROSENWALD LINDSAY A MD | Director, Officer, 10% owner | BUY | $1.85 | 136,723 | $252,582 | 4,723,564 |
| 2026-11-19 23:04 | 2026-11-18 | BMRN | BIOMARIN PHARMACEUTICAL INC | Friberg Gregory R | Officer | SELL | $58.81 | 5,147 | $302,711 | 42,585 |
| 2026-11-19 22:54 | 2026-11-17 | FBIO | Fortress Biotech, Inc. | Jin David | Officer | BUY | $1.84 | 47,605 | $87,812 | 1,700,366 |
| 2026-11-19 22:07 | 2026-11-17 | ELVN | Enliven Therapeutics, Inc. | Collins Helen Louise | Officer | OPT+S | $46.84 | 5,000 | $234,203 | 25,000 |
| 2026-11-19 21:40 | 2026-11-17 | ACRV | Acrivon Therapeutics, Inc. | Gamelin Erick | Officer | SELL | $1.45 | 416 | $603 | 52,176 |
| 2026-11-19 21:41 | 2026-11-18 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer | OPT+S | $578.83 | 5,410 | $3,131,476 | 324,443 |
| 2026-11-19 21:41 | 2026-11-17 | ACRV | Acrivon Therapeutics, Inc. | Miller Mary | Officer | SELL | $1.45 | 193 | $280 | 81,009 |
| 2026-11-19 21:42 | 2026-11-17 | AVLN | Avalyn Pharma Inc. | Lazarus Howard | Officer | OPT+S | $27.90 | 13,300 | $371,027 | 0 |
| 2026-11-19 21:43 | 2026-11-17 | ACRV | Acrivon Therapeutics, Inc. | Peterson Katharine | Officer | SELL | $1.45 | 107 | $155 | 17,926 |
| 2026-11-19 21:52 | 2026-11-18 | NMAD | NOMAD POWER SOLUTIONS, INC. | Travaglini John Francis | Director | BUY | $2.85 | 5,000 | $14,270 | 5,000 |
| 2026-11-19 21:35 | 2026-11-19 | ZOMDF | Zomedica Corp. | POWERS JOHNNY D | Director | BUY | $0.08 | 175,000 | $14,525 | 4,600,000 |
| 2026-11-19 21:38 | 2026-11-17 | ACRV | Acrivon Therapeutics, Inc. | Blume-Jensen Peter | Director, Officer | SELL | $1.45 | 1,780 | $2,581 | 385,355 |
| 2026-11-19 21:39 | 2026-11-17 | ACRV | Acrivon Therapeutics, Inc. | Devroe Eric | Officer | SELL | $1.45 | 628 | $911 | 145,721 |
| 2026-11-19 21:10 | 2026-11-17 | KROS | Keros Therapeutics, Inc. | Prener Anne | Director | SELL | $10.83 | 575 | $6,230 | 12,637 |
| 2026-11-19 21:10 | 2026-11-17 | KROS | Keros Therapeutics, Inc. | Newton Charles W. | Director | SELL | $10.85 | 551 | $5,981 | 11,563 |
Sector-Wide Insider Alpha
Analyzing insider movements across the Pharmaceutical Preparations sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2834) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in Pharmaceutical Preparations
Every transaction in the Pharmaceutical Preparations industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.